Synvista Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1986-01-01
- Employees
- 11
- Market Cap
- -
- Website
- https://www.alteon.com
Efficacy and Safety of Topical ALT-2074 (SYI-2074) for Treatment of Chronic Plaque Psoriasis
- Conditions
- Psoriasis
- Interventions
- Drug: 4,4-dimethyl-benziso-2H-selenazineDrug: Placebo
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2009-01-30
- Lead Sponsor
- Synvista Therapeutics, Inc
- Target Recruit Count
- 30
- Registration Number
- NCT00782613
- Locations
- 🇮🇱
Ha'emek Medical Center, Afula, Israel
🇮🇱Kaplan Medical Center, Rechovot, Israel
🇮🇱Chaim Sheba Medical Center, Tel Hashomer, Israel
Safety & Efficacy of ALT-711 (Alagebrium) in Chronic Heart Failure
- First Posted Date
- 2008-08-22
- Last Posted Date
- 2009-01-30
- Lead Sponsor
- Synvista Therapeutics, Inc
- Target Recruit Count
- 100
- Registration Number
- NCT00739687
- Locations
- 🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸Medical University of South Carolina (MUSC), Charleston, South Carolina, United States
🇺🇸Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
Beginning a Randomized Evaluation of the AGE Breaker Alagebrium in Diastolic Heart Failure (BREAK-DHF-I)
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2009-01-30
- Lead Sponsor
- Synvista Therapeutics, Inc
- Target Recruit Count
- 160
- Registration Number
- NCT00662116
Study of Alagebrium in Patients With Insulin-Dependent Type 1 Diabetes and Microalbuminuria
- Conditions
- Diabetes Mellitus, Type 1Diabetic Nephropathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2009-01-30
- Lead Sponsor
- Synvista Therapeutics, Inc
- Target Recruit Count
- 80
- Registration Number
- NCT00557518
- Locations
- 🇦🇺
Dept. of Clinical and Biomedical Science Myers House, Geelong, Victoria, Australia
🇦🇺The Alfred Hospital, Melbourne, Victoria, Australia
🇦🇺Austin Health, Heidelburg, Victoria, Australia
The BENEFICIAL Study: Evaluating the Efficacy and Safety of Alagebrium (ALT-711) in Patients With Chronic Heart Failure
- First Posted Date
- 2007-08-15
- Last Posted Date
- 2010-01-13
- Lead Sponsor
- Synvista Therapeutics, Inc
- Target Recruit Count
- 100
- Registration Number
- NCT00516646
- Locations
- 🇳🇱
Dept. Cardiology - University Medical Center Groningen, Groningen, P.O. Box 30 001, Netherlands
Evaluation of ALT-2074 in Subjects With Type-2 Diabetes, Haptoglobin Type 2-2 Genotype and Coronary Artery Disease
- Conditions
- DiabetesCoronary Artery Disease
- First Posted Date
- 2007-06-26
- Last Posted Date
- 2008-07-02
- Lead Sponsor
- Synvista Therapeutics, Inc
- Target Recruit Count
- 66
- Registration Number
- NCT00491543
- Locations
- 🇺🇸
Radiant Research, Cincinnati, Ohio, United States
A Phase 2 Study to Determine the Effects of BXT-51072 in Diabetic Patients Undergoing Angioplasty (PCI)
- Conditions
- Acute Coronary SyndromeType 2 Diabetes
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2008-08-25
- Lead Sponsor
- Synvista Therapeutics, Inc
- Target Recruit Count
- 60
- Registration Number
- NCT00320502
- Locations
- 🇮🇱
Western Galilee Hospital, Nahariya, Israel
🇮🇱Rivka Sieff Hospital, Safed, Israel
🇮🇱Rambam Medical Center, Haifa, Israel
The STRETCH Study: Distensibility on Endothelial-Dependent Vasoreactivity in Subjects With Systolic Hypertension
- Conditions
- Cardiovascular Disease
- First Posted Date
- 2006-03-14
- Last Posted Date
- 2006-03-22
- Lead Sponsor
- Synvista Therapeutics, Inc
- Target Recruit Count
- 70
- Registration Number
- NCT00302250
- Locations
- 🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
STRETCH Study: Effect of Distensibility on Endothelial-Dependent Vasoreactivity in Patients With ISH
- Conditions
- Cardiovascular Disease
- First Posted Date
- 2006-01-18
- Last Posted Date
- 2009-08-27
- Lead Sponsor
- Synvista Therapeutics, Inc
- Target Recruit Count
- 25
- Registration Number
- NCT00277875
- Locations
- 🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
Systolic Pressure Efficacy and Safety Trial of Alagebrium (SPECTRA)
- Conditions
- Hypertension
- First Posted Date
- 2004-08-12
- Last Posted Date
- 2010-02-08
- Lead Sponsor
- Synvista Therapeutics, Inc
- Target Recruit Count
- 392
- Registration Number
- NCT00089713
- Locations
- 🇺🇸
Alteon Inc., Parsippany, New Jersey, United States